2022
Oxalate homeostasis
Ermer T, Nazzal L, Tio M, Waikar S, Aronson P, Knauf F. Oxalate homeostasis. Nature Reviews Nephrology 2022, 19: 123-138. PMID: 36329260, PMCID: PMC10278040, DOI: 10.1038/s41581-022-00643-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsKidney diseaseOxalate homeostasisAnti-inflammatory medicationsChronic kidney diseaseKidney replacement therapySudden cardiac deathProgressive kidney diseaseOutlook of patientsOxalate nephropathyCardiovascular complicationsSystemic inflammationCardiac deathReplacement therapySecondary hyperoxaluriaKidney failureElevated plasmaConsequent impairmentNovel therapeuticsPatientsDiseaseEffective elimination strategiesEndogenous sourcesHomeostasisElimination strategyExcretionHemodialysis and biotransformation of erythrocyte epoxy fatty acids in peripheral tissue
Liu T, Dogan I, Rothe M, Kunz J, Knauf F, Gollasch M, Luft F, Gollasch B. Hemodialysis and biotransformation of erythrocyte epoxy fatty acids in peripheral tissue. Prostaglandins Leukotrienes And Essential Fatty Acids 2022, 181: 102453. PMID: 35633593, DOI: 10.1016/j.plefa.2022.102453.Peer-Reviewed Original ResearchConceptsRed blood cellsHD treatmentHemodialysis treatmentEnd-stage renal disease patientsHydroxyeicosatetraenoic acidHydroxyeicosapentaenoic acidSingle hemodialysis treatmentChronic kidney diseaseRenal disease patientsRenal replacement therapyFatty acid statusVenous blood samplesHydroxydocosahexaenoic acidEpoxy fatty acidsCause of mortalityLOX pathwayRenal failureFatty acidsKidney diseaseDisease patientsVenous bloodCardiovascular functionAcid statusArteriovenous differenceCardiovascular diseaseBioaccumulation of Blood Long-Chain Fatty Acids during Hemodialysis
Liu T, Dogan I, Rothe M, Reichardt J, Knauf F, Gollasch M, Luft F, Gollasch B. Bioaccumulation of Blood Long-Chain Fatty Acids during Hemodialysis. Metabolites 2022, 12: 269. PMID: 35323712, PMCID: PMC8949028, DOI: 10.3390/metabo12030269.Peer-Reviewed Original ResearchChronic kidney diseaseRed blood cellsLong-chain fatty acidsHD treatmentUpper limbEnd-stage renal disease patientsPeripheral tissue perfusionSingle HD treatmentRenal disease patientsFatty acid statusVenous blood samplesFatty acidsCardiovascular eventsESRD patientsHD patientsKidney diseaseDisease patientsVenous bloodHemodialysis treatmentAcid statusUremia altersBlood samplesTissue perfusionLCFA levelsFatty acids n
2021
Determinants and Outcomes Associated With Urinary Calcium Excretion in Chronic Kidney Disease
Liu J, Tio M, Verma A, Schmidt I, Ilori T, Knauf F, Mc Causland F, Waikar S. Determinants and Outcomes Associated With Urinary Calcium Excretion in Chronic Kidney Disease. The Journal Of Clinical Endocrinology & Metabolism 2021, 107: e281-e292. PMID: 34390334, PMCID: PMC8684460, DOI: 10.1210/clinem/dgab574.Peer-Reviewed Original ResearchConceptsUrinary calcium excretionChronic kidney diseaseEnd-stage kidney diseaseCalcium excretionKidney diseaseChronic Renal Insufficiency Cohort (CRIC) StudyIncident end-stage kidney diseaseLevel of CKDSelf-identified black raceAtherosclerotic cardiovascular disease eventsSerum parathyroid hormoneCardiovascular disease eventsAdverse clinical eventsAdverse clinical outcomesStage kidney diseaseBaseline eGFRCKD progressionUrinary sodiumCause mortalityCohort studyLoop diureticsThiazide diureticsClinical outcomesParathyroid hormoneVascular calcification
2020
Assessment of Plasma Oxalate Concentration in Patients With CKD
Pfau A, Wytopil M, Chauhan K, Reichel M, Coca SG, Aronson PS, Eckardt KU, Knauf F. Assessment of Plasma Oxalate Concentration in Patients With CKD. Kidney International Reports 2020, 5: 2013-2020. PMID: 33163722, PMCID: PMC7609998, DOI: 10.1016/j.ekir.2020.08.029.Peer-Reviewed Original ResearchChronic kidney diseasePlasma oxalate concentrationGerman Chronic Kidney Disease (GCKD) studyChronic Kidney Disease studyObservational cohort studyGlomerular filtration rateLarge patient cohortKidney Disease studyKidney stone diseaseCKD progressionMedian eGFROngoing multicenterCohort studyKidney diseasePatient cohortPresent studyFiltration rateClinical trialsStone diseaseLarge cohortOxalate homeostasisPatientsDisease StudyPlasma samplesMaintenance of samplesStiripentol fails to lower plasma oxalate in a dialysis-dependent PH1 patient
Kempf C, Pfau A, Holle J, Müller-Schlüter K, Bufler P, Knauf F, Müller D. Stiripentol fails to lower plasma oxalate in a dialysis-dependent PH1 patient. Pediatric Nephrology 2020, 35: 1787-1789. PMID: 32418144, PMCID: PMC7385015, DOI: 10.1007/s00467-020-04585-5.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseChronic kidney diseaseLactate dehydrogenase 5Urinary oxalateAdvanced chronic kidney diseaseAnti-convulsive drugsMultisystemic metabolic disorderLiver-kidney transplantationMajority of patientsCurrent standard treatmentTreatment of childrenHyperoxaluria type 1Anuric infantsPH patientsUox excretionRenal diseaseDravet syndromeKidney diseasePrimary hyperoxaluriaCompassionate useStandard treatmentPlasma concentrationsMetabolic disordersPromising drugEarly infancy
2019
Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation
Egli-Spichtig D, Imenez Silva P, Glaudemans B, Gehring N, Bettoni C, Zhang M, Pastor-Arroyo E, Schönenberger D, Rajski M, Hoogewijs D, Knauf F, Misselwitz B, Frey-Wagner I, Rogler G, Ackermann D, Ponte B, Pruijm M, Leichtle A, Fiedler G, Bochud M, Ballotta V, Hofmann S, Perwad F, Föller M, Lang F, Wenger R, Frew I, Wagner C. Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation. Kidney International 2019, 96: 890-905. PMID: 31301888, DOI: 10.1016/j.kint.2019.04.009.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnimalsCell LineCohort StudiesDisease Models, AnimalFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsHumansInflammatory Bowel DiseasesInterleukin-10KidneyMaleMiceMice, TransgenicMiddle AgedNuclear Receptor Subfamily 4, Group A, Member 2Primary Cell CultureRenal Insufficiency, ChronicTumor Necrosis Factor-alphaConceptsChronic kidney diseaseTumor necrosis factorPlasma FGF23Kidney diseaseFGF23 expressionFGF23 levelsNecrosis factorGrowth factor 23 levelsFibroblast growth factor 23Inflammatory cytokines tumor necrosis factorCytokines tumor necrosis factorInflammatory bowel diseaseGrowth factor 23Normal kidney functionIL10-deficient micePopulation-based cohortAntibody-mediated neutralizationOrphan nuclear receptor Nurr1Nuclear receptor Nurr1Cause mortalityRenal inflammationTNF neutralizationBowel diseaseFactor 23Kidney function
2016
Oxalate, inflammasome, and progression of kidney disease
Ermer T, Eckardt KU, Aronson PS, Knauf F. Oxalate, inflammasome, and progression of kidney disease. Current Opinion In Nephrology & Hypertension 2016, 25: 363-371. PMID: 27191349, PMCID: PMC4891250, DOI: 10.1097/mnh.0000000000000229.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseProgressive renal failureRenal inflammationRenal failurePlasma oxalateKidney diseaseInflammasome activationElevated plasma oxalate levelsNOD-like receptor familyProgressive renal damageGlomerular filtration rateMore rapid progressionWarrants clinical trialsPlasma oxalate levelsRenal damageEnteric hyperoxaluriaMacrophage infiltrationIL-1βFiltration rateClinical trialsRapid progressionInflammasome proteinsMice protectsUrinary oxalatePyrin domainOxalate-induced chronic kidney disease with its uremic and cardiovascular complications in C57BL/6 mice
Mulay SR, Eberhard JN, Pfann V, Marschner JA, Darisipudi MN, Daniel C, Romoli S, Desai J, Grigorescu M, Kumar SV, Rathkolb B, Wolf E, Hrabě de Angelis M, Bäuerle T, Dietel B, Wagner CA, Amann K, Eckardt KU, Aronson PS, Anders HJ, Knauf F. Oxalate-induced chronic kidney disease with its uremic and cardiovascular complications in C57BL/6 mice. American Journal Of Physiology. Renal Physiology 2016, 310: f785-f795. PMID: 26764204, PMCID: PMC5504458, DOI: 10.1152/ajprenal.00488.2015.Peer-Reviewed Original ResearchConceptsC57BL/6 miceChronic kidney disease researchOxalate-rich dietChronic kidney diseaseFemale C57BL/6 miceArterial hypertensionCardiovascular complicationsKidney disease researchAtubular glomeruliInterstitial inflammationRenal histologyTubular damageKidney diseaseCardiac fibrosisMetabolic acidosisNormochromic anemiaTissue involvementHistological changesHuman CKDCKDExperimental animalsComplicationsInducible modelControl dietFibrosis